Epigenetics of depression

Progress in Molecular Biology and Translational Science

Volumn 128, Issue C, 2014, Pages 103-137

  Lolak, Sermsak ^a   Suwannarat, Pim ^b   Lipsky, Robert H ^c,d  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b KAISER PERMANENTE MEDICAL CENTER   (United States)

^c BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

^d GEORGE MASON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; DESIPRAMINE; DEXAMETHASONE; DOPAMINE; ESCITALOPRAM; FK 506 BINDING PROTEIN; FLUOXETINE; NEUROTROPHIN; NORADRENALIN; SEROTONIN; SEROTONIN TRANSPORTER;

ANIMAL MODEL; CLINICAL TRIAL (TOPIC); COMORBIDITY; DEMOGRAPHY; DEPRESSION; EARLY LIFE STRESS; ENVIRONMENTAL FACTOR; EPIGENETICS; GENETIC ASSOCIATION; GENETIC MANIPULATION; GENETIC REGULATION; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LONG TERM CARE; MAJOR DEPRESSION; META ANALYSIS (TOPIC); NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEX DIFFERENCE; TREATMENT RESPONSE;

EID: 84927738137     PISSN: 18771173     EISSN: 18780814     Source Type: Book Series    
DOI: 10.1016/B978-0-12-800977-2.00005-X     Document Type: Chapter

References (144)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Publishing; 2013.
2. Uher R, Payne JL, Pavlova B, Perlis RH. Major depressive disorder in DSM-5: implications for clinical practice and research of changes from DSM-IV. Depress Anxiety. 2013;31:459-471.
3. Uher R. Genomics and the classification of mental illness: focus on broader categories. Genome Med. 2013;5:97.
4. Whiteford HA, Degenhardt L, Rehm J, et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet. 2013;382:1575-1586.
5. Murray CJL, Lopez AD. The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries and Risk Factors in 1990 and Projected to 2020. Geneva, Switzerland: World Health Organization; 1996.
6. Kessler RC, Bromet EJ. The epidemiology of depression across cultures. Annu Rev Public Health. 2013;34:119-138.
7. Kessler RC, Berglund PA, Demler O, Jin R, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication (NCS-R). Arch Gen Psychiatry. 2005;62:593-602.
8. Bromet E, Andrade LH, Hwang I, et al. Cross-national epidemiology of DSM-IV major depressive episode. BMC Med. 2011;9:90.
9. Dalva MB, McClelland AC, Kayser MS. Cell adhesion molecules: signaling functions at the synapse. Nat Rev Neurosci. 2007;8:206-220.
10. El-Hage W, Leman S, Camus V, Belzung C. Mechanisms of antidepressant resistance. Front Pharmacol. 2013;4:146.
11. Shores MM, Kivlahan DR, Sadak TI, Li EJ, Matsumoto AM. A randomized, doubleblind, placebo-controlled study of testosterone treatment in hypogonadal older men with subthreshold depression (dysthymia or minor depression). J Clin Psychiatry. 2009;70:1009-1016.
12. Cohen LS, Soares CN, Vitonis AF, Otto MW, Harlow BL. Risk for new onset of depression during the menopausal transition: the Harvard study of moods and cycles. Arch Gen Psychiatry. 2006;63:385-390.
13. Goel N, Bale TL. Examining the intersection of sex and stress in modeling neuropsychiatric disorders. J Neuroendocrinol. 2009;21:415-420.
14. Kessler RC. The costs of depression. Psychiatr Clin North Am. 2012;35:1-14.
15. Pozuelo L, Tesar G, Zhang J, Penn M, Franco K, Jiang W. Depression and heart disease: what do we know, and where are we headed? Cleve Clin J Med. 2009;76:59-70.
16. Sher Y, Lolak S, Maldonado JR. The impact of depression in heart disease. Curr Psychiatry Rep. 2010;12:255-264.
17. Charney DS. Monoamine dysfunction and the pathophysiology and treatment of depression. J Clin Psychiatry. 1998;14:11-14.
18. Krishnan V, Nestler EJ. Linking molecules to mood: new insight into the biology of depression. Am J Psychiatry. 2010;167:1305-1320.
19. Trivedi MH, Rush AJ, Wisniekski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR∗D: implications for clinical practice. Am J Psychiatry. 2006;163:28-40.
20. Murrough JW, Iosifescu DV, Chang LC, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. 2013;170:1134-1142.
21. Egan MF, Kojima M, Callicott JH, et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell. 2003;112:257-269.
22. Laje G, Lally N, Mathews D, et al. Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients. Biol Psychiatry. 2012;72:e27-e28.
23. Lipsky RH, Marini AM. Brain-derived neurotrophic factor in neuronal survival and behavior-related plasticity. Ann N Y Acad Sci. 2007;1122:130-143.
24. Neumeister A, Yuan P, Yound TA, et al. Effects of tryptophan depletion on serum levels of brain-derived neurotrophic factor in unmedicated patients with remitted depression and healthy subjects. Am J Psychiatry. 2005;162:805-807.
25. Mann JJ, Currier D. Effects of genes and stress on the neurobiology of depression. Int Rev Neurobiol. 2006;73:153-189.
26. Hayley S, Litteljohn D. Neuroplasticity and the next wave of antidepressant strategies. Front Cell Neurosci. 2013;7:218.
27. Shimizu E, Hashimoto K, Okamura N, et al. Alterations of serum levels of brainderived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry. 2003;54:70-75.
28. Sun H, Kennedy PJ, Nestler EJ. Epigenetics of the depressed brain: role of histone acetylation and methylation. Neuropsychopharmacology. 2013;38:124-137.
29. Dedoni S, Olianas MC, Ingianni A, Onali P. Type I interferons impair BDNF-induced cell signaling and neurotrophic activity in differentiated human SH-SY5Y neuroblastoma cells and mouse primary cortical neurons. J Neurochem. 2012;122:58-71.
30. Berton O, McClung CA, Dileone RJ, et al. Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science. 2006;31:864-868.
31. Martocchia A, Curto M, Scaccianoce S, et al. Effects of escitalopram on serum BDNF levels in elderly patients with depression: a preliminary report. Aging Clin Exp Res. 2014;26(4):461-464.
32. Pittenger C, Duman RS. Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology. 2008;33:88-109.
33. Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature. 2008;455:894-902.
34. Wainwright SR, Galea LA. The neural plasticity theory of depression: assessing the roles of adult neurogenesis and PSA-NCAM within the hippocampus. Neural Plast. 2013;2013:805497.
35. Holsboer F.The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 2000;23:477-501.
36. Henckens MJ, van Wingen GA, Joëls M, Fernández G. Time-dependent corticosteroid modulation of prefrontal working memory processing. Proc Natl Acad Sci USA. 2011;108:5801-5806.
37. Yuen EY, Liu W, Karatsoreos IN, Feng J, McEwen BS, Yann Z. Acute stress enhances glutamatergic transmission in prefrontal cortex and facilitates working memory. Proc Natl Acad Sci USA. 2009;106:14075-14079.
38. Crowley GT, Khatami M, Vasavada N. The dexamethasone suppression test in patients with mood disorders. J Clin Psychiatry. 1996;57:470-484.
39. Mellsop GW, Hutton JD, Delahunt JW. Dexamethasone suppression test as a simple measure of stress? Br Med J (Clin Res Ed). 1985;290:1804-1806.
40. Brown WA, Shuey I. Response to dexamethasone and subtype of depression. Arch Gen Psychiatry. 1980;37:747-751.
41. Rush AJ, Giles DE, Schlesser MA, et al. The dexamethasone suppression test in patients with mood disorders. J Clin Psychiatry. 1996;57:470-484.
42. Behnken A, Bellingrath S, Symanczik JP, et al. Associations between cognitive performance and cortisol reaction to the DEX/CRH test in patients recovered from depression. Psychoneuroendocrinology. 2013;38:447-454.
43. Wilkinson CW, Peskind ER, Raskind MA. Decreased hypothalamic-pituitary-adrenal axis sensitivity to cortisol feedback inhibition in human aging. Neuroendocrinology. 1997;65:79-90.
44. Zovato S, Simoncini M, Gottardo C, et al. Dexamethasone suppression test: corticosteroid receptors regulation in mononuclear leukocytes in young and aged subjects. Aging. 1996;8:360-364. http://www.who.int/mediacentre/factsheets/fs369/en/[accessed December, 2013].
45. Colla M, Kronenberg G, Deuschle M, et al. Hippocampal volume reduction and HPAsystem activity in major depression. J Psychiatr Res. 2007;41:553-560.
46. MacQueen GM, Yucel K, Taylor VH, Macdonald K, Joffe R. Posterior hippocampal volumes are associated with remission rates in patients with major depressive disorder. Biol Psychiatry. 2008;64:880-883.
47. Drevets WC, Price JL, Furey ML. Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct Funct. 2008;213:93-118.
48. Sapolsky RM. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry. 2000;57:925-935.
49. Frodl T, O'Keane V. How does the brain deal with cumulative stress? A review with focus on developmental stress, HPA axis function and hippocampal structure in humans. Neurobiol Dis. 2013;52:24-37.
50. Kelly WF, Kelly MJ, Faragher B. A prospective study of psychiatric and psychological aspects of Cushing's syndrome. Clin Endocrinol (Oxf ). 1996;45:715-720.
51. Ragnarsson O, Berglund P, Eder DN, Hohannsson G. Long-term cognitive impairments and attention deficits in patients with Cushing's disease and cortisol-producing adrenal adenoma in remission. J Clin Endocrinol Metab. 2012;97:E1640-E1648.
52. Ising M, Horstmann S, Kloiber S, et al. Combined dexamethasone/corticotropin releasing hormone test predicts treatment response in major depression-a potential biomarker? Biol Psychiatry. 2007;62:47-54.
53. Snyder JS, Soumier A, Brewer M, Pickel J, Cameron HA. Adult hippocampal neurogenesis buffers stress responses and depressive behaviour. Nature. 2011;476:458-461.
54. Van Kampen M, Kramer M, Hiemke C, Flügge G, Fuchs E. The chronic psychosocial stress paradigm in male tree shrews: evaluation of a novel animal model for depressive disorders. Stress. 2002;5:37-46.
55. Fuchs E, Flügge G. Social stress in tree shrews: effects on physiology, brain function, and behavior of subordinate individuals. Pharmacol Biochem Behav. 2002;7:247-258.
56. American Psychiatric Association. APA Practice Guideline for the Treatment of Patients with Major Depressive Disorder. 3rd ed. Arlington, Virginia: American Psychiatric Association; 2013. http://www.psychiatryonline.com/pracGuide/pracGuideTopic-7.aspx [accessed December, 2013].
57. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR∗D report. Am J Psychiatry. 2006;163:1905-1917.
58. Lam RW. Onset, time course and trajectories of improvement with antidepressants. Eur Neuropsychopharmacol. 2012;22(Suppl. 3):S492-S498.
59. Menke A, Klengel T, Binder EB. Epigenetics, depression and antidepressant treatment. Curr Pharm Des. 2012;18:5879-5889.
60. Tsankova N, Renthal W, Kumar A, Nestler EJ. Epigenetic regulation in psychiatric disorders. Nat Rev Neurosci. 2007;8:355-367.
61. El Hage W, Powell JF, Surguladze SA. Vulnerability to depression: what is the role of stress genes in gene x environment interaction? Psychol Med. 2009;39: 1407-1411.
62. Santarelli L, Saxe M, Gross C, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science. 2003;301:805-809.
63. Bessa JM, Ferreira D, Melo I, et al. The mood-improving actions of antidepressants do not depend on neurogenesis but are associated with neuronal remodeling. Mol Psychiatry. 2009;14:764-773.
64. Tang SW, Helmeste D, Leonard B. Is neurogenesis relevant in depression and in the mechanism of antidepressant drug action? A critical review. World J Biol Psychiatry. 2012;13:402-412.
65. Perera TD, Coplan JD, Lisanby SH, et al. Antidepressant-induced neurogenesis in the hippocampus of adult nonhuman primates. J Neurosci. 2007;27:4894-4901.
66. McGuffin P, Cohen S, Knight J. Homing in on depression genes. Am J Psychiatry. 2007;164:195-197.
67. Shyn SI, Hamilton SP. The genetics of major depression: moving beyond the monoamine hypothesis. Psychiatr Clin North Am. 2010;33:125-140.
68. Shyn SI, Shi J, Kraft JB, et al. Novel loci for major depression identified by genomewide association study of Sequenced Treatment Alternatives to Relieve Depression and meta-analysis of three studies. Mol Psychiatry. 2011;16:202-215.
69. Crisafulli C, Fabbri C, Porcelli S, et al. Pharmacogenetics of antidepressants. Front Pharmacol. 2011;2:6.
70. Hu X, Lipsky RH, Zhu G, et al. Gain-of-function genotypes are linked to obsessivecompulsive disorder. Am J Hum Genet. 2006;78:815-826.
71. Lesch KP, Bengel D, Heils A, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science. 1996;2(74): 1527-1531.
72. Levinson DF. The genetics of depression: a review. Biol Psychiatry. 2006;60:84-92.
73. Hu X-Z, Rush AJ, Charney D, et al. Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Arch Gen Psychiatry. 2007;64:783-792.
74. McMahon FJ, Buervenich S, Charney D, et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet. 2006;78:804-814.
75. Mrazek DA, Rush AJ, Biernacka JM, et al. SLC6A4 variation and citalopram response. Am J Med Genet B Neuropsychiatr Genet. 2009;150B:341-351.
76. Karg K, Burmeister M, Shedden K, Sen S. The serotonin transporter promoter variant (5-HTTLPR), stress, and depression meta-analysis revisited: evidence of genetic moderation. Arch Gen Psychiatry. 2011;68:444-454.
77. Hu X, Tian F, Ecklund JM, Lipsky RH. Differential responsiveness of the serotonin transporter gene in pharmacologic treatment of adult depression: potential for understanding epigenetic-genetic interactions. In: Gordon Research Conference, Human Genetics and Genomics July 17-22; 2011.
78. Dudbridge F, Gusnanto A. Estimation of significance thresholds for genomewide association scans. Genet Epidemiol. 2008;32:227-234.
79. Major Depressive Disorder Working Group of the Psychiatric GWAS Consortium, Ripke S, Wray NR, et al. A mega-analysis of genome-wide association studies for major depressive disorder. Mol Psychiatry. 2013;18:497-511.
80. Singh AB, Bousman CA, Ng C, Berk M. Antidepressant pharmacogenetics. Curr Opin Psychiatry. 2014;27:43-51.
81. Shi Y, Yuan Y, Xu Z, et al. Genetic variation in the calcium/calmodulin-dependent protein kinase (CaMK) pathway is associated with antidepressant response in females. J Affect Disord. 2012;136:558-566.
82. Singh AB, Bousman CA, Ng CH, Byron K, Berk M. ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression. Transl Psychiatry. 2012;2: e198.
83. Laje G, McMahon FJ. Genome-wide association studies of antidepressant outcome: a brief review. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35:1553-1557.
84. Garriock HA, Kraft JB, Shyn SI, et al. A genomewide association study of citalopram response in major depressive disorder. Biol Psychiatry. 2010;167:133-138.
85. Ising M, Lucae S, Binder EB, et al. A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch Gen Psychiatry. 2009;66:966-975.
86. Uher R, Perroud N, Ng MY, et al. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am J Psychiatry. 2010;167:555-564.
87. Serretti A, Kato M, De Ronchi D, Kinoshita T. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry. 2007;12(3):247-257.
88. Taylor MJ, Sen S, Bhagwagar Z. Antidepressant response and the serotonin transporter gene-linked polymorphic region. Biol Psychiatry. 2010;68:536-543.
89. Porcelli S, Fabbri C, Serretti A. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. Eur Neuropsychopharmacol. 2012;22(4):239-258.
90. Binder EB, Salyakina D, Lichtner P, et al. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet. 2004;36:1319-1325.
91. Binder EB. The role of FKBP5, a co-chaperone of the glucocorticoid receptor in the pathogenesis and therapy of affective and anxiety disorders. Psychoneuroendocrinology. 2009;34(Suppl. 1):S186-S195.
92. Lekman M, Laje G, Charney D, et al. The FKBP5-gene in depression and treatment response-an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR∗D) Cohort. Biol Psychiatry. 2008;63:1103-1110.
93. Klengel T, Mehta D, Anacker C, et al. Allele-specific FKBP5 DNA demethylation mediates gene-childhood trauma interactions. Nat Neurosci. 2013;16:33-41.
94. Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatry. 2000;157:1552-1562.
95. Bonanno GA, Galea S, Bucciarelli A, Vlahov D. What predicts psychological resilience after disaster? The role of demographics, resources, and life stress. J Consult Clin Psychol. 2007;7:671-682.
96. Fossion P, Leys C, Kempenaers C, Braun S, Verbanck P, Linkowski P. Depression, anxiety and loss of resilience after multiple traumas: an illustration of a mediated moderation model of sensitization in a group of children who survived the Nazi Holocaust. J Affect Disord. 2013;151:973-979.
97. Caspi A, Sugden K, Moffitt TE, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science. 2003;18:386-389.
98. Risch N, Herrell R, Lehner T, et al. Interaction between the serotonin transporter gene (5-HTTLPR), stressful life events, and risk of depression: a meta-analysis. JAMA. 2009;301:2462-2471.
99. Weaver IC, Cervoni N, Champagne FA, et al. Epigenetic programming by maternal behavior. Nat Neurosci. 2004;7:847-854.
100. Fraga MF, Ballestar E, Paz MF, et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci USA. 2005;102:10604-10609.
101. Ruhe HG, Mason NS, Schene AH. Mood is indirectly related to serotonin, norepinephrine, and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Mol Psychiatry. 2007;12:331-359.
102. Watanabe Y, Gould E, McEwen BS. Stress induces atrophy of apical dendrites of hippocampal CA3 pyramidal neurons. Brain Res. 1992;588:341-345.
103. Chen WG, Chang Q, Lin Y, et al. Derepression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2. Science. 2003;302:885-889.
104. Lipsky RH, Xu K, Zhu D, et al. Nuclear factor kappaB is a critical determinant in N-methyl-D-aspartate receptor-mediated neuroprotection. J Neurochem. 2001;78: 254-264.
105. Martinowich K, Hattor I, Wu H, et al. DNA methylation-related chromatin remodeling in activity-dependent BDNF gene regulation. Science. 2003;302:890-893.
106. Timmusk T, Belluardo N, Persson H, Metsis M. Developmental regulation of brainderived neurotrophic factor messenger RNAs transcribed from different promoters in the rat brain. Neuroscience. 1994;60:287-291.
107. Jiang X, Zhou J, Mash DC, Marini AM, Lipsky RH. Human BDNF isoforms are differentially expressed in cocaine addicts and are sorted to the regulated secretory pathway independent of the Met66 substitution. Neuromol Med. 2009;11:1-12.
108. Liu QR, Lu L, Zhu XG, Gong JP, Shaham Y, Uhl GR. Rodent BDNF genes, novel promoters, novel splice variants, and regulation by cocaine. Brain Res. 2006;1067:1-12.
109. Marini AM, Jiang X, Wu X, et al. Role of brain-derived neurotrophic factor and NF-kappaB in neuronal plasticity and survival: from genes to phenotype. Restor Neurol Neurosci. 2004;22:121-130.
110. Lipsky RH. Epigenetic mechanisms regulating learning and long-term memory. Int J Dev Neurosci. 2013;31:353-358.
111. Roth TL, Lubin FD, Funk AJ, Sweatt JD. Lasting epigenetic influence of early-life adversity on the BDNF gene. Biol Psychiatry. 2009;65:760-769.
112. Kozicz T, Tilburg-Ouwens D, Faludi G, Palkovits M, Roubos E. Genderrelated urocortin 1 and brain-derived neurotrophic factor expression in the adult human midbrain of suicide victims with depression. Neuroscience. 2008;152: 1015-1023.
113. Chen B, Dowlatshahi D, MacQueen GM, Wang JF, Young LT. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry. 2001;50:260-265.
114. Kavalali ET, Monteggia LM. Synaptic mechanisms underlying rapid antidepressant action of ketamine. Am J Psychiatry. 2012;169:1150-1156.
115. Guiddotti G, Calabrese F, Anacker C, Racagni G, Pariante CM, Riva MA. Glucocorticoid receptor and FKBP5 expression is altered following exposure to chronic stress: modulation by antidepressant treatment. Neuropsychopharmacology. 2013;38:616-627.
116. Tsankova NM, Kumar A, Nestler EJ. Histone modifications at gene promoter regions in rat hippocampus after acute and chronic electroconvulsive seizures. J Neurosci. 2004;24:5603-5610.
117. Tsankova NM, Berton O, Renthal W, Kumar A, Neve RL, Nestler EJ. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci. 2006;9:519-525.
118. Karpova NN, Lindolm J, Prunnsild P, Timmusk T, Castren E. Long-lasting behavioural and molecular alterations induced by early postnatal fluoxetine exposure are restored by chronic fluoxetine treatment in adult mice. Eur Neuropsychopharmacol. 2009;19:97-108.
119. Farah A. The role of L-methylfolate in depressive disorders. CNS Spectr. 2009;14:2-7.
120. Baubec T, Ivánek R, Lienert F, Schübeler D. Methylation-dependent and -independent genomic targeting principles of the MBD protein family. Cell. 2013;153:480-492.
121. Chahrour M, Jung SY, Shaw C, et al. MeCP2, a key contributor to neurological disease, activates and represses transcription. Science. 2008;320:1224-1229.
122. Chang Q, Khare G, Dani V, Nelson S, Jaenisch R. The disease progression of Mecp2 mutant mice is affected by the level of BDNF expression. Neuron. 2006;49:341-348.
123. Uddin M, Koenen KC, Aiello AE, Wildman DE, de los Santos R, Galea S. Epigenetic and inflammatory marker profiles associated with depression in a community-based epidemiologic sample. Psychol Med. 2011;41:997-1007.
124. Gold SM, Irwin MR. Depression and immunity: inflammation and depressive symptoms in multiple sclerosis. Immunol Allergy Clin North Am. 2009;29:309-320.
125. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2009;65:732-741.
126. Sabunciyan S, Aryee MJ, Irizarry RA, et al. Genome-wide DNA methylation scan in major depressive disorder. PLoS One. 2012;7:e34451.
127. Kohen R, Dobra A, Tracy JH, Haugen E. Transcriptome profiling of human hippocampus dentate gyrus granule cells in mental illness. Transl Psychiatry. 2014;4:e366.
128. Szyf M. Epigenetics, DNA methylation, and chromatin modifying drugs. Annu Rev Pharmacol Toxicol. 2009;49:243-263.
129. Guintivano J, Aryee MJ, Kaminsky ZA. A cell epigenotype specific model for the correction of brain cellular heterogeneity bias and its application to age, brain region and major depression. Epigenetics. 2013;8:290-302.
130. Ladd-Acosta C, Pevsner J, Sabunciyan S, et al. DNA methylation signatures within the human brain. Am J Hum Genet. 2007;81:1304-1315.
131. Bayles R, Baker EK, Jowett JBM, Barton D, Esler M, El-Osta A, Lambert G. Methylation of the SLC6a2 gene promoter in major depression and panic disorder. PLoS One. 2012;8:e83223.
132. Archer T, Oscar-Berman M, Blum K, Gold M. Epigenetic modulation of mood disorders. J Genet Syndr Gene Ther. 2013;11:4(120).
133. Yu H, Wang DD, Wang Y, Liu T, Lee FS, Chen ZY. Variant brain-derived neurotrophic factor Val66Met polymorphism alters vulnerability to stress and response to antidepressants. J Neurosci. 2012;32:4092-4101.
134. Dhobale M, Joshi S. Altered maternal micronutrients (folic acid, vitamin B(12)) and omega 3 fatty acids through oxidative stress may reduce neurotrophic factors in preterm pregnancy. J Matern Fetal Neonatal Med. 2012;25:317-323.
135. Toffoli LV, Rodrigues Jr GM, Oliveira JF, et al. Maternal exposure to fluoxetine during gestation and lactation affects the DNA methylation programming of rat's offspring: modulation by folic acid supplementation. Behav Brain Res. 2014;265: 142-147.
136. Fava M, Mischoulon D. Folate in depression: efficacy, safety, differences in formulations, and clinical issues. J Clin Psychiatry. 2009;70:12-17.
137. Morris DW, Trivedi MH, Rush AJ. Folate and unipolar depression. J Altern Complement Med. 2008;14:277-285.
138. Papakostas GI, Shelton RC, Zajecka JM, et al. Effect of adjunctive L-methylfolate 15 mg among inadequate responders to SSRIs in depressed patients who were stratified by biomarker levels and genotype: results from a randomized clinical trial. J Clin Psychiatry. 2014;75:855-863.
139. De Berardis D, Marini S, Serroni N, et al. S-Adenosyl-L-methionine augmentation in patients with stage II treatment-resistant major depressive disorder: an open label, fixed dose, single-blind study. ScientificWorldJournal. 2013;2013:204649.
140. Papakostas GI, Mischoulon D, Shyu I, Alpert JE, Fava M. S-Adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. Am J Psychiatry. 2010;167:942-948.
141. Sarris J, Papakostas GI, Vitolo O, Fava M, Mischoulon D. S-Adenosyl methionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response. J Affect Disord. 2014;164:76-81.
142. Papakostas GI. Evidence for S-adenosyl-L-methionine (SAM-e) for the treatment of major depressive disorder. J Clin Psychiatry. 2009;70(Suppl. 5):18-22.
143. Papakostas GI, Cassiello CF, Iovieno N. Folates and S-adenosylmethionine for major depressive disorder. Can J Psychiatry. 2012;57:406-413.
144. Gvozdic K, Brandl EJ, Taylor DL, Mü ller DJ. Genetics and personalized medicine in antidepressant treatment. Curr Pharm Des. 2012;18:5853-5878.